Monash IVF (ASX:MVF) share price up 3% on guidance beating profits

The ASX healthcare share delivered its full year financial results this morning.

| More on:
A little boy, soon to be a brother, kisses and holds his mum's pregnant tummy.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Monash IVF Group Ltd (ASX: MVF) share price is gaining in intraday trade, up 3% to 99 cents per share.

This follows on the release of the reproductive services provider's results for the 2021 financial year ending 30 June (FY21).

Monash IVF share price gains on FY21 results

  • Revenue of $183.6 million, increased 26.3% from $145.4 million in FY20
  • Adjusted earnings before interest, taxes, depreciation and amortisation (EBITDA) increased 37.1% to $47.7 million
  • Adjusted net profits after tax (NPAT) increased 61.5% to $23.3 million, beating guidance of $21-23 million
  • Reported NPAT increased 16.9% to $25.5 million
  • $32.8 million of Free Cash Flow generation

What happened during the reporting period for Monash IVF?

Over the course of the 2021 financial year, Monash IVF reported a 36.6% increase in the number of its Australian Stimulated Cycles (STIMS). It attributed much of this to broader industry growth as well as the company making some market share gains.

Internationally its STIMS numbers reached 208 cycles, up 25.1% year-on-year.

Ultrasound scan volumes also performed strongly compared to FY20, increasing by 12.9%.

Monash IVF also opened its flagship clinic in Sydney and appointed 5 Fertility Specialists and a Medical Director of Genetics. The company flagged additional new clinics opening in FY22.

The company said that the first quarter of the financial year saw it servicing the pent-up demand from deferred IVF treatments, which had been temporarily suspended during the early COVID lockdowns.

What did management say?

Commenting on the results, Monash IVF's CEO, Michael Knaap said:

Our FY21 financial performance was strong and ahead of market expectations and was driven not just by strong industry growth, but also through implementing our own growth initiatives to increase our market share and build for future sustainable growth…

We believe there is a fundamental shift in the community whereby the on-going Pandemic has changed the mindset of our patient cohort, leading to greater focus on family, health and wellbeing and resulting in re-direction of priorities towards family extension. This shift is driving industry growth and is expected to continue.

Knapp said the company has improved its clinical pregnancy rates by 4.5% since 2018, "following a huge amount of effort put into improving outcomes for our patients including harmonisation of laboratory protocols and new innovation".

What's next for Monash IVF?

Monash IVF said its strong balance sheet puts it in a good position to get through the ongoing pandemic, as well as optimising "future earnings through strategic and operational gains" made during the past financial year.

Based on there being no major increase in adverse impacts from the pandemic, management is "confident" the company can grow revenue and earnings in FY22.

Knapp said, "With a growing pipeline of new patient enquiries and registrations, we are confident and well placed for sustainable future growth."

The Monash IVF share price is up 68% over the past 12 months.

The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Earnings Results

A man sits thoughtfully on the couch with a laptop on his lap.
Technology Shares

Up 74% in 2024, why is this ASX 200 stock rallying today?

Recurring revenues continue to grow.

Read more »

Man pointing at a blue rising share price graph.
Earnings Results

Guess which ASX All Ords share is soaring on 21% FY 2024 growth

Investors are piling into the ASX All Ords share today. Let’s find out why.

Read more »

Girl sliding down on snow with arms spread out.
Earnings Results

Elders shares on ice for a $475 million acquisition after profits plunge 55%

What on earth is going on with Elders shares today?

Read more »

A man has a surprised and relieved expression on his face. as he raises his hands up to his face in response to the high fluctuations in the Galileo share price today
Energy Shares

This ASX 200 mining stock just reported a 40% earnings jump

Investors appear pleased with this miner's performance during the first quarter.

Read more »

Business people discussing project on digital tablet.
Earnings Results

2 ASX All Ords shares surging over 10% on strong results

Investors are buying these shares in response to strong results this morning.

Read more »

A young woman holds her hand to her mouth in surprise as she reads something on her laptop.
Earnings Results

Xero share price rockets to record high on explosive half-year growth

The tech star delivered another impressive half year results this morning.

Read more »

A man cheers after winning computer game while woman sitting next to him looks upset.
Earnings Results

2 high-flying ASX 200 gaming shares splitting ways today

Which gaming giant is winning the admiration of investors amid results?

Read more »

Male building supervisor wearing high vis vest and hard hat stands and smiles with his arms crossed at a building site
Industrials Shares

This $23 billion ASX 200 stock is surging 6% while the market sinks. Here's why

This ASX 200 stock is shrugging off the wider market sell down today and racing higher. But why?

Read more »